Universidad del País Vasco/Euskal Herriko Unibertsitatea-ko ikertzaileekin lankidetzan egindako argitalpenak (21)

2024

  1. A genome-wide association analysis reveals new pathogenic pathways in gout*

    Nature Genetics

2023

  1. Mechanisms and rationale for uricase use in patients with gout

    Nature Reviews Rheumatology, Vol. 19, Núm. 10, pp. 640-649

  2. The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease

    Arthritis and Rheumatology, Vol. 75, Núm. 10, pp. 1703-1713

  3. The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease

    Annals of the Rheumatic Diseases, Vol. 82, Núm. 10, pp. 1248-1257

2022

  1. Crystal-Associated Arthritis: Gout

    Synovial Fluid Analysis and the Evaluation of Patients with Arthritis (Springer International Publishing), pp. 91-100

  2. Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study

    Clinical Rheumatology, Vol. 41, Núm. 12, pp. 3817-3823

  3. Gout. What's up doc?

    Medicina Clinica, Vol. 158, Núm. 12, pp. 615-621

  4. One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study

    Arthritis Research and Therapy, Vol. 24, Núm. 1

2020

  1. High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?

    Rheumatology and Therapy, Vol. 7, Núm. 4, pp. 1011-1019

  2. Understanding the patient voice in gout: A quantitative study conducted in Europe

    BJGP Open, Vol. 4, Núm. 1

2019

  1. Gout

    Rheumatic Disease Clinics of North America, Vol. 45, Núm. 4, pp. 583-591

  2. Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 11, pp. 1592-1600

  3. Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout

    Arthritis Care and Research, Vol. 71, Núm. 3, pp. 427-434

  4. Second-line treatment with lesinurad and allopurinol versus febuxostat for management of hyperuricemia: a cost-effectiveness analysis for Spanish patients

    Clinical Rheumatology, Vol. 38, Núm. 12, pp. 3521-3528

2018

  1. Brief Report: Validation of a Definition of Flare in Patients With Established Gout

    Arthritis and Rheumatology, Vol. 70, Núm. 3, pp. 462-467

  2. Improvement in Diagnosis and Treat-to-Target Management of Hyperuricemia in Gout: Results from the GEMA-2 Transversal Study on Practice

    Rheumatology and Therapy, Vol. 5, Núm. 1, pp. 243-253

  3. International position paper on the appropriate use of uricosurics with the introduction of lesinurad

    Clinical Rheumatology, Vol. 37, Núm. 12, pp. 3159-3165

  4. La réponse rénale aux variations de l'uricémie est différente chez les patients goutteux comparativement aux sujets sains

    Revue du Rhumatisme (Edition Francaise), Vol. 85, Núm. 1, pp. 79-84

  5. Treat to Target

    Gout (Elsevier), pp. 179-183

2015

  1. Hyperuricaemia with deposition: Latest evidence and therapeutic approach

    Therapeutic Advances in Musculoskeletal Disease, Vol. 7, Núm. 6, pp. 225-233